APA

Zugmaier G., Topp M. S., Alekar S., Viardot A., Horst H., Neumann S., Stelljes M., Bargou R. C., Goebeler M., Wessiepe D., Degenhard E., Gökbuget N. & Klinger M. (20150916). Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. : Blood cancer journal.

Chicago

Zugmaier G, Topp M S, Alekar S, Viardot A, Horst H-A, Neumann S, Stelljes M, Bargou R C, Goebeler M, Wessiepe D, Degenhard E, Gökbuget N and Klinger M. 20150916. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. : Blood cancer journal.

Harvard

Zugmaier G., Topp M. S., Alekar S., Viardot A., Horst H., Neumann S., Stelljes M., Bargou R. C., Goebeler M., Wessiepe D., Degenhard E., Gökbuget N. and Klinger M. (20150916). Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. : Blood cancer journal.

MLA

Zugmaier G, Topp M S, Alekar S, Viardot A, Horst H-A, Neumann S, Stelljes M, Bargou R C, Goebeler M, Wessiepe D, Degenhard E, Gökbuget N and Klinger M. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. : Blood cancer journal. 20150916.